Durham biotech company Metabolon announced this morning that it secured $6 million in venture capital funding to finance operations.
The latest round of venture capital brings the company's total haul to about $31 million since 2003.
Metabolon was incorporated in 2000 and today employs 52 people, mostly in Durham. The company is run by CEO John Ryals, who previously was founder and CEO of Paradigm Genetics.
Metabolon has two lines of business. Its service branch provides analytical tools that measure biochemicals to assess the severity of a disease. Metabolon's diagnostics branch expects to have its first product -- a diagnostic tool for prostate cancer -- on the market in early 2011.
The latest financing added new investors including Syngenta Ventures, the corporate venture capital subsidiary of Syngenta. Its local investors include the Aurora Funds and Fulcrum Financial Partners.